Drug Trial Radar · NCT06287567
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Apr 17, 2024
Primary completion
Nov 13, 2024
Study completion Mar 6, 2025
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy
Conditions
- Idiopathic Thrombocytopenic Purpura
- Immune Thrombocytopenia
Interventions
Lusutrombopag Oral TabletDrug
Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg(2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with a Platelet Response after 4 WeeksTime frame: on Day 29 of Treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.